Member Info for Bella6532

Bfdinvestor. So those comments made by AS during your visit are what Myles M has based his X on re BBC and Sky etc.

MM said over the next couple of weeks, so did AS say the data would be released once QC'd?

Thanks for a tad more clarification.

The London Stock Exchange suffered a second trading outage today as it was hit by an “incident” on its trading information system.

Only the FTSE 100, FTSE 250 and IOB securities are available for trading following the latest outage.

A similar incident affected about 2,000 stocks, including the likes of Asos and Deliveroo, for about half an hour this morning.

Interesting opening line from MM...'Personal view is that, over the next two weeks, @avacta

's #AVA6000 Phase 1a trial is covered by mainstream media -

@BBCNews', @SkyNews, etc.'

Mmmm...Miles you don't say 'My' personal view...so whose personal view is it?

The only way the BBC and Sky would be reporting on the AVA6000 trial (and I note you don't say trial data) over the next two weeks particularly prior to 13th, is if they get a PR or a freelance reporter has been sniffing around putting something together or you (Miles) have or a mate of yours has been fed the info etc. Over the next two weeks does imply before the 13th and afterwards otherwise you would have said 13th onwards.

Investor Meet are the ones who will have asked for or insisted on an announcment being made this morning to get new sign ups/generate interest and for them to sort through/filter the questions. The RNS contains nothing more or less than is needed by Investor Meet.

Now as far as Avacta is concerned, they still have a few more days to add something more to the party if they wish or if they can. The 13th can be purely to do with AVA6000 basic data or if they choose to release more information between now and 13th such as completion of C7 etc they can do so at their own pace or when the information becomes available like FDA etc.....OR they can just concentrate on AVA6000 data and let that alone speak for itself on the day to create the most impact without other information getting in the way.

Yes we would all like to see more, but, we will just have to wait and see how this pans out...

It's how they always do it...

Data will be RNS'd on 13th the same day as Investor Meet....just as they've done with results.

LiveLongnProsper...on both there is a button 'Check for Updates'. When Avacta RNS their AVA6000 data will they also send it to the AARC Journal as an update?

CaptainS...ask yourself why they are here...

Large trades going thru...lots of derampers...no coincidence...

Oh...there's the little rascal...just popped up...haha

01-Dec-23 16:19:03 135.229 91,591 Buy* 134.00 136.00 123.86k

StarBright...a joke hun...a joke...

OilNovice...Dox is a killer drug...it not only attack tumours/cancerous cells it attack good cells too especially vunerable heart cells...

In the form of AVA6000 the good cells are protected from the killer dox...

What a great piece of marketing for BP...'we can kill the bad bits without killing the patient'...

And as they say...please now DYOR

OilNovice...BP are big businesses and in serious competition with each other. Sometimes commercial decisions are not purely based on returns but keeping up with their competitors. Being able to offer the oncologists Dox in a format that targets the FAP in the cancerous cells/tumours at 3 to 4 times a dosage than Dox can be administered right now with very few side effects with the potential of actually shrinking the tumour(s) rather than the killing the patient is huge. AVA6000 is the start. There are lots of examples of little companies out there who developed great product and take up was slow but once one biggie jumped in others followed. BP are a nervous bunch and like sheep, when one breaks out the rest are sure to follow...ARM is a case in point and very much like Avacta when it comes to their licencing strategy.

And more balancing the books trades...wink wink...!!

29-Nov-23 14:22:53 136.00 20,000 Unknown* 27.20k O

29-Nov-23 14:23:09 137.90 30,000 Unknown* 41.37k O

29-Nov-23 08:37:00 136.00 75,000 Unknown* 102.00k O

30-Nov-23 17:07:23 137.00 6,000 Unknown* 8,220 O

30-Nov-23 16:56:50 137.007 2,145 Unknown* 2,939

Apologies if this has been mentioned...

If Dox can be administered in AVA6000 in 3/4 times the current dosage (with very few side effects) , in 2 week rather than 3 week intervals and if it's able to seek out and distroy all the istzy bitzy cancer cells throughout the body which often get missed leading to an extention of life with perhaps overall fewer doses, less hospital time/follow ups etc etc...then that has to be a win win for both patients, the hospitals and BP....fingers and toes crossed we have such a product.

Side effects in themselves have a cost as often other drugs have to be administered alongside the dox to help minimise them and/or meds prescribed to take between treatments etc...

Also many patients give up on their treatments due to the side effects or their bodies won't tolerate max doses and if give lower does risk low efficacy or even drug resistance. There's also the possbility of infection or other diseases taking hold as dox affects the immune system....and so on..

From 28th and 29th...balancing books!!!

29-Nov-23 16:00:34 136.675 12,500 Unknown* 17.08k O

28-Nov-23 16:29:39 138.00 49,325 Unknown* 68.07k O

28-Nov-23 14:54:30 138.00 21,625 Unknown* 29.84k O

28-Nov-23 15:11:23 138.00 25,000 Unknown* 34.50k O

29-Nov-23 15:13:24 136.50 15,000 Unknown* 20.48k O

29-Nov-23 14:59:47 136.50 15,000 Unknown* 20.48k O

29-Nov-23 16:55:16 136.014 35,545 Unknown* 48.35k

'Dr. Coughlin has held other leadership roles in the pharmaceutical and biotechnology fields in her career including Oncology Asset Team Leader at Pfizer and Clinical Program Team Lead at Novartis.'

Published Aug 23

https://www.linkedin.com/pulse/doxorubicin-market-size-outlook-keyplayers-johnson

And someone is getting ready for something...absolutely not a coincidence...

27-Nov-23 08:01:01 140.50 55,000 Unknown* 77.28k O

27-Nov-23 16:10:36 140.00 210,348 Unknown* 294.49k O

27-Nov-23 11:21:43 140.215 25,000 Unknown* 35.05k O

27-Nov-23 08:13:09 140.65 100,000 Unknown* 140.65k O

27-Nov-23 11:47:34 140.15 25,000 Unknown* 35.04k O

27-Nov-23 12:41:24 140.25 50,000 Unknown* 70.13k O

27-Nov-23 10:11:14 140.515 25,000 Unknown* 35.13k O

28-Nov-23 16:56:50 138.007 207 Unknown* 285.67 O

28-Nov-23 16:56:24 138.986 10,171 Unknown* 14.14k O

28-Nov-23 16:55:00 138.986 10,171 Unknown* 14.14k O

28-Nov-23 16:35:00 138.00 10,504 Sell*

Timster...yes he did (scroll down to end of this post)...what room are you in?

'It is not a question of follow the money, but follow the volume and then listen to what the company tells at AGM’ s etc.

Fiona McLaughlin’s presentation in Boston and what companies like Lilly is up to!

We got a company who I have always said it is the best thing out of Cambridge ( used to have office there) since ARM holdings.

There is a persistent buyer in the market and now will seriously have the majors stop taking no for an answer.

Avacta has told us once latest Cohort is out, next stop is a licensed deal and reorganise the company ( diagnostics) and we are off to the races.It is Friday, next week will heavy volume and suddenly no sellers. Classic situation! Seen it many times before, why do you think management have not been selling!

You have 30 min left and that will be the last time you can get in at these prices.Get on board and the trick is not to sell too early!!

Look at some of the US Biotech stocks and what happen to them.

Who can out bid most of the others ? JNJ is one of them.

Good luck, but buy now !!'

Thanks Hurstbot...an upfront deal like that would certainly be far better than another fundraise which AS seemed to put to bed as not being necessary/needed.

Lilly would be a natural...but as you say JNJ has the derpest pockets.

Ophidian..JNJ and/or L??

The latter obviously being the closest link...but JNJ is an interesting thought...